Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP664683.RA-DlcvjSYty5kp4E_Xt8ksckeQx4RtfkOq03PYN5bQrg130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP664683.RA-DlcvjSYty5kp4E_Xt8ksckeQx4RtfkOq03PYN5bQrg130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP664683.RA-DlcvjSYty5kp4E_Xt8ksckeQx4RtfkOq03PYN5bQrg130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP664683.RA-DlcvjSYty5kp4E_Xt8ksckeQx4RtfkOq03PYN5bQrg130_provenance.
- NP664683.RA-DlcvjSYty5kp4E_Xt8ksckeQx4RtfkOq03PYN5bQrg130_assertion description "[The phase II SRC/ABL Tyrosine Kinase Inhibition Activity Research Trials (START) of dasatinib have established dasatinib as potent and effective in overcoming imatinib resistance or intolerance in all phases of CML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP664683.RA-DlcvjSYty5kp4E_Xt8ksckeQx4RtfkOq03PYN5bQrg130_provenance.
- NP664683.RA-DlcvjSYty5kp4E_Xt8ksckeQx4RtfkOq03PYN5bQrg130_assertion evidence source_evidence_literature NP664683.RA-DlcvjSYty5kp4E_Xt8ksckeQx4RtfkOq03PYN5bQrg130_provenance.
- NP664683.RA-DlcvjSYty5kp4E_Xt8ksckeQx4RtfkOq03PYN5bQrg130_assertion SIO_000772 18397680 NP664683.RA-DlcvjSYty5kp4E_Xt8ksckeQx4RtfkOq03PYN5bQrg130_provenance.
- NP664683.RA-DlcvjSYty5kp4E_Xt8ksckeQx4RtfkOq03PYN5bQrg130_assertion wasDerivedFrom befree-2016 NP664683.RA-DlcvjSYty5kp4E_Xt8ksckeQx4RtfkOq03PYN5bQrg130_provenance.
- NP664683.RA-DlcvjSYty5kp4E_Xt8ksckeQx4RtfkOq03PYN5bQrg130_assertion wasGeneratedBy ECO_0000203 NP664683.RA-DlcvjSYty5kp4E_Xt8ksckeQx4RtfkOq03PYN5bQrg130_provenance.
- befree-2016 importedOn "2016-02-19" NP664683.RA-DlcvjSYty5kp4E_Xt8ksckeQx4RtfkOq03PYN5bQrg130_provenance.